Rout Twinkle, Singh Aalapti, Epari Venkatarao, Mohanty Debiprasad, Sahu Manoj, Nayak Priya, Ludam Rakhi, Tudu Promod, Agrawala Sunil
Department of Surgical Oncology, Institute of Medical Sciences and SUM Hospital, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha India.
Department of Community Medicine, Institute of Medical Sciences and SUM Hospital, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha India.
Indian J Otolaryngol Head Neck Surg. 2022 Oct;74(Suppl 2):2430-2434. doi: 10.1007/s12070-020-02185-1. Epub 2020 Oct 14.
Human epidermal growth factor receptor 2/neu (HER2/neu) is known to serve as a prognostic and predictive biomarker in several cancers such as breast, gastric and ovarian cancers. In head and neck squamous cell carcinoma, HER2/neu expression is seen but in a fluctuated manner. Hence, its role as a prognostic factor in oral squamous cell carcinoma (OSCC) needs evaluation. To determine the HER 2/neu overexpression in OSCC patients and its association with clinical and pathological parameters. 74 patients of OSCC treated between 2016 and 2018 were included in the study. Immunohistochemistry was done on tissue samples from these patients and HER2/neu expression was measured. Both biopsy and resected specimens were considered for the study. Out of 74 patients, 47.3% (35) were operated and 52.7% (39) were not operated due to loss to follow-up. No significant association was found ( = 0.636, OR = 0.68, CI = 0.14-3.34) between lymphovascular invasion (LVI) and HER2/neu expression. Similar results were seen for perineural invasion (PNI) ( = 0.490, OR = 0.53, CI = 0.88-3.24), depth of invasion ( = 0.21), grade of tumor ( = 0.214), clinical-stage ( = 0.511) and pathological stage ( = 0.091). No significant association existed between HER2/neu expression and LVI, PNI, clinical-stage, the grade of tumor and the pathological stage of oral squamous cell carcinoma.
人表皮生长因子受体2/neu（HER2/neu）在乳腺癌、胃癌和卵巢癌等多种癌症中是一种预后和预测生物标志物。在头颈部鳞状细胞癌中，可见HER2/neu表达，但呈波动状态。因此，其在口腔鳞状细胞癌（OSCC）中作为预后因素的作用需要评估。为了确定OSCC患者中HER2/neu的过表达及其与临床和病理参数的关联。本研究纳入了2016年至2018年间接受治疗的74例OSCC患者。对这些患者的组织样本进行免疫组织化学检测并测量HER2/neu表达。活检和切除标本均纳入研究。74例患者中，47.3%（35例）接受了手术，52.7%（39例）因失访未接受手术。在淋巴管浸润（LVI）与HER2/neu表达之间未发现显著关联（P = 0.636，OR = 0.68，CI = 0.14 - 3.34）。神经周围浸润（PNI）的结果相似（P = 0.490，OR = 0.53，CI = 0.88 - 3.24），浸润深度（P = 0.21）、肿瘤分级（P = 0.214）、临床分期（P = 0.511）和病理分期（P = 0.091）也是如此。HER2/neu表达与口腔鳞状细胞癌的LVI、PNI、临床分期、肿瘤分级和病理分期之间不存在显著关联。
